Loading…
Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2
Vitamin C (L-ascorbic acid, ascorbate, VC) is a potential chemotherapeutic agent for cancer patients. However, the anti-tumor effects of pharmacologic VC on hepatocellular carcinoma (HCC) and liver cancer stem cells (CSCs) remain to be fully elucidated. Panels of human HCC cell lines as well as HCC...
Saved in:
| Published in: | NPJ precision oncology 2018-01, Vol.2 (1), p.1-1, Article 1 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c536t-4d41d2d460902625f8a08eef21d8a9966f2d21ddbbb325e6d14efe5903c55be73 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c536t-4d41d2d460902625f8a08eef21d8a9966f2d21ddbbb325e6d14efe5903c55be73 |
| container_end_page | 1 |
| container_issue | 1 |
| container_start_page | 1 |
| container_title | NPJ precision oncology |
| container_volume | 2 |
| creator | Lv, Hongwei Wang, Changzheng Fang, Tian Li, Ting Lv, Guishuai Han, Qin Yang, Wen Wang, Hongyang |
| description | Vitamin C (L-ascorbic acid, ascorbate, VC) is a potential chemotherapeutic agent for cancer patients. However, the anti-tumor effects of pharmacologic VC on hepatocellular carcinoma (HCC) and liver cancer stem cells (CSCs) remain to be fully elucidated. Panels of human HCC cell lines as well as HCC patient-derived xenograft (PDX) models were employed to investigate the anti-tumor effects of pharmacologic VC. The use of VC and the risk of HCC recurrence were examined retrospectively in 613 HCC patients who received curative liver resection as their initial treatment. In vitro and in vivo experiments further demonstrated that clinically achievable concentrations of VC induced cell death in liver cancer cells and the response to VC was correlated with sodium-dependent vitamin C transporter 2 (SVCT-2) expressions. Mechanistically, VC uptake via SVCT-2 increased intracellular ROS, and subsequently caused DNA damage and ATP depletion, leading to cell cycle arrest and apoptosis. Most importantly, SVCT-2 was highly expressed in liver CSCs, which promoted their self-renewal and rendered them more sensitive to VC. In HCC cell lines xenograft models, as well as in PDX models, VC dramatically impaired tumor growth and eradicated liver CSCs. Finally, retrospective cohort study showed that intravenous VC use was linked to improved disease-free survival (DFS) in HCC patients (adjusted HR = 0.622, 95% CI 0.487 to 0.795,
p
|
| doi_str_mv | 10.1038/s41698-017-0044-8 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5871898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2389705333</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-4d41d2d460902625f8a08eef21d8a9966f2d21ddbbb325e6d14efe5903c55be73</originalsourceid><addsrcrecordid>eNp1kUtLxDAUhYMoKuP8ADdScOOmepPmuRFk8AWCC3V0F9I21WgfY9IO-O9NGd9gNnncLyfn5iC0i-EQQyaPAsVcyRSwSAEoTeUa2iaZEqng8mH9x3oLTUN4BgAsGSacb6ItoqQggsA2up-73jSuTWbJwtvKetv2ztT1W_Li6jokhWkL65PQ2yYp7HgS2Se7MH03bofa-Mj4wrVdY5KlM8nNfHabkh20UZk62OnHPEF3Z6e3s4v06vr8cnZylRYs431KS4pLUlIOCggnrJIGpLUVwaU0SnFekTKuyzzPM8IsLzGNJpmCrGAstyKboOOV7mLIG1sW0b43tV541xj_pjvj9O9K6570Y7fUTAoslYwCBx8CvnsdbOh148LYmmltNwRNgGHggkoa0f0_6HM3-Da2p0kmlQCWxTFBeEUVvgsh_umXGQx6TE6vktMxOT0mp0cTez-7-LrxmVMEyAoIsdQ-Wv_99P-q72VBpEk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2389705333</pqid></control><display><type>article</type><title>Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Lv, Hongwei ; Wang, Changzheng ; Fang, Tian ; Li, Ting ; Lv, Guishuai ; Han, Qin ; Yang, Wen ; Wang, Hongyang</creator><creatorcontrib>Lv, Hongwei ; Wang, Changzheng ; Fang, Tian ; Li, Ting ; Lv, Guishuai ; Han, Qin ; Yang, Wen ; Wang, Hongyang</creatorcontrib><description>Vitamin C (L-ascorbic acid, ascorbate, VC) is a potential chemotherapeutic agent for cancer patients. However, the anti-tumor effects of pharmacologic VC on hepatocellular carcinoma (HCC) and liver cancer stem cells (CSCs) remain to be fully elucidated. Panels of human HCC cell lines as well as HCC patient-derived xenograft (PDX) models were employed to investigate the anti-tumor effects of pharmacologic VC. The use of VC and the risk of HCC recurrence were examined retrospectively in 613 HCC patients who received curative liver resection as their initial treatment. In vitro and in vivo experiments further demonstrated that clinically achievable concentrations of VC induced cell death in liver cancer cells and the response to VC was correlated with sodium-dependent vitamin C transporter 2 (SVCT-2) expressions. Mechanistically, VC uptake via SVCT-2 increased intracellular ROS, and subsequently caused DNA damage and ATP depletion, leading to cell cycle arrest and apoptosis. Most importantly, SVCT-2 was highly expressed in liver CSCs, which promoted their self-renewal and rendered them more sensitive to VC. In HCC cell lines xenograft models, as well as in PDX models, VC dramatically impaired tumor growth and eradicated liver CSCs. Finally, retrospective cohort study showed that intravenous VC use was linked to improved disease-free survival (DFS) in HCC patients (adjusted HR = 0.622, 95% CI 0.487 to 0.795,
p
< 0.001). Our data highlight that pharmacologic VC can effectively kill liver cancer cells and preferentially eradicate liver CSCs, which provide further evidence supporting VC as a novel therapeutic strategy for HCC treatment.
Liver cancer: vitamin C preferentially kills cancer stem cells and improves patient outcomes
Pharmacologic doses of vitamin C preferentially eradicate liver cancer stem cells and are associated with improved outcomes in patients. A team led by Hong-Yang Wang and Wen Yang from the Second Military Medical University in Shanghai, China, showed that clinically achievable concentrations of vitamin C effectively killed liver cancer cells and preferentially eradicated cancer stem cells in culture and in mouse transplant models. Cells with higher expression levels of a vitamin C transporter protein were more susceptible to the treatment, which explains why cancer stem cells, which highly express this transportor and use it for their own self-renewal, were especially sensitive to take in vitamin C, which led to a cascade that resulted in DNA damage, energy depletion, and ultimately cell death. A retrospective analysis of 613 patients with liver cancer showed that those who received intravenous vitamin C lived longer without disease relapse.</description><identifier>ISSN: 2397-768X</identifier><identifier>EISSN: 2397-768X</identifier><identifier>DOI: 10.1038/s41698-017-0044-8</identifier><identifier>PMID: 29872720</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1059 ; 631/67/71 ; Apoptosis ; Cancer Research ; Cell cycle ; DNA damage ; Gene Therapy ; Human Genetics ; Internal Medicine ; Liver cancer ; Medicine ; Medicine & Public Health ; Oncology ; Patients ; Precision medicine ; Stem cells ; Targeted cancer therapy ; Vitamin C</subject><ispartof>NPJ precision oncology, 2018-01, Vol.2 (1), p.1-1, Article 1</ispartof><rights>The Author(s) 2018</rights><rights>The Author(s) 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-4d41d2d460902625f8a08eef21d8a9966f2d21ddbbb325e6d14efe5903c55be73</citedby><cites>FETCH-LOGICAL-c536t-4d41d2d460902625f8a08eef21d8a9966f2d21ddbbb325e6d14efe5903c55be73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871898/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2389705333?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29872720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lv, Hongwei</creatorcontrib><creatorcontrib>Wang, Changzheng</creatorcontrib><creatorcontrib>Fang, Tian</creatorcontrib><creatorcontrib>Li, Ting</creatorcontrib><creatorcontrib>Lv, Guishuai</creatorcontrib><creatorcontrib>Han, Qin</creatorcontrib><creatorcontrib>Yang, Wen</creatorcontrib><creatorcontrib>Wang, Hongyang</creatorcontrib><title>Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2</title><title>NPJ precision oncology</title><addtitle>npj Precision Onc</addtitle><addtitle>NPJ Precis Oncol</addtitle><description>Vitamin C (L-ascorbic acid, ascorbate, VC) is a potential chemotherapeutic agent for cancer patients. However, the anti-tumor effects of pharmacologic VC on hepatocellular carcinoma (HCC) and liver cancer stem cells (CSCs) remain to be fully elucidated. Panels of human HCC cell lines as well as HCC patient-derived xenograft (PDX) models were employed to investigate the anti-tumor effects of pharmacologic VC. The use of VC and the risk of HCC recurrence were examined retrospectively in 613 HCC patients who received curative liver resection as their initial treatment. In vitro and in vivo experiments further demonstrated that clinically achievable concentrations of VC induced cell death in liver cancer cells and the response to VC was correlated with sodium-dependent vitamin C transporter 2 (SVCT-2) expressions. Mechanistically, VC uptake via SVCT-2 increased intracellular ROS, and subsequently caused DNA damage and ATP depletion, leading to cell cycle arrest and apoptosis. Most importantly, SVCT-2 was highly expressed in liver CSCs, which promoted their self-renewal and rendered them more sensitive to VC. In HCC cell lines xenograft models, as well as in PDX models, VC dramatically impaired tumor growth and eradicated liver CSCs. Finally, retrospective cohort study showed that intravenous VC use was linked to improved disease-free survival (DFS) in HCC patients (adjusted HR = 0.622, 95% CI 0.487 to 0.795,
p
< 0.001). Our data highlight that pharmacologic VC can effectively kill liver cancer cells and preferentially eradicate liver CSCs, which provide further evidence supporting VC as a novel therapeutic strategy for HCC treatment.
Liver cancer: vitamin C preferentially kills cancer stem cells and improves patient outcomes
Pharmacologic doses of vitamin C preferentially eradicate liver cancer stem cells and are associated with improved outcomes in patients. A team led by Hong-Yang Wang and Wen Yang from the Second Military Medical University in Shanghai, China, showed that clinically achievable concentrations of vitamin C effectively killed liver cancer cells and preferentially eradicated cancer stem cells in culture and in mouse transplant models. Cells with higher expression levels of a vitamin C transporter protein were more susceptible to the treatment, which explains why cancer stem cells, which highly express this transportor and use it for their own self-renewal, were especially sensitive to take in vitamin C, which led to a cascade that resulted in DNA damage, energy depletion, and ultimately cell death. A retrospective analysis of 613 patients with liver cancer showed that those who received intravenous vitamin C lived longer without disease relapse.</description><subject>631/67/1059</subject><subject>631/67/71</subject><subject>Apoptosis</subject><subject>Cancer Research</subject><subject>Cell cycle</subject><subject>DNA damage</subject><subject>Gene Therapy</subject><subject>Human Genetics</subject><subject>Internal Medicine</subject><subject>Liver cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Stem cells</subject><subject>Targeted cancer therapy</subject><subject>Vitamin C</subject><issn>2397-768X</issn><issn>2397-768X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp1kUtLxDAUhYMoKuP8ADdScOOmepPmuRFk8AWCC3V0F9I21WgfY9IO-O9NGd9gNnncLyfn5iC0i-EQQyaPAsVcyRSwSAEoTeUa2iaZEqng8mH9x3oLTUN4BgAsGSacb6ItoqQggsA2up-73jSuTWbJwtvKetv2ztT1W_Li6jokhWkL65PQ2yYp7HgS2Se7MH03bofa-Mj4wrVdY5KlM8nNfHabkh20UZk62OnHPEF3Z6e3s4v06vr8cnZylRYs431KS4pLUlIOCggnrJIGpLUVwaU0SnFekTKuyzzPM8IsLzGNJpmCrGAstyKboOOV7mLIG1sW0b43tV541xj_pjvj9O9K6570Y7fUTAoslYwCBx8CvnsdbOh148LYmmltNwRNgGHggkoa0f0_6HM3-Da2p0kmlQCWxTFBeEUVvgsh_umXGQx6TE6vktMxOT0mp0cTez-7-LrxmVMEyAoIsdQ-Wv_99P-q72VBpEk</recordid><startdate>20180108</startdate><enddate>20180108</enddate><creator>Lv, Hongwei</creator><creator>Wang, Changzheng</creator><creator>Fang, Tian</creator><creator>Li, Ting</creator><creator>Lv, Guishuai</creator><creator>Han, Qin</creator><creator>Yang, Wen</creator><creator>Wang, Hongyang</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180108</creationdate><title>Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2</title><author>Lv, Hongwei ; Wang, Changzheng ; Fang, Tian ; Li, Ting ; Lv, Guishuai ; Han, Qin ; Yang, Wen ; Wang, Hongyang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-4d41d2d460902625f8a08eef21d8a9966f2d21ddbbb325e6d14efe5903c55be73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>631/67/1059</topic><topic>631/67/71</topic><topic>Apoptosis</topic><topic>Cancer Research</topic><topic>Cell cycle</topic><topic>DNA damage</topic><topic>Gene Therapy</topic><topic>Human Genetics</topic><topic>Internal Medicine</topic><topic>Liver cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Stem cells</topic><topic>Targeted cancer therapy</topic><topic>Vitamin C</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lv, Hongwei</creatorcontrib><creatorcontrib>Wang, Changzheng</creatorcontrib><creatorcontrib>Fang, Tian</creatorcontrib><creatorcontrib>Li, Ting</creatorcontrib><creatorcontrib>Lv, Guishuai</creatorcontrib><creatorcontrib>Han, Qin</creatorcontrib><creatorcontrib>Yang, Wen</creatorcontrib><creatorcontrib>Wang, Hongyang</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>NPJ precision oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lv, Hongwei</au><au>Wang, Changzheng</au><au>Fang, Tian</au><au>Li, Ting</au><au>Lv, Guishuai</au><au>Han, Qin</au><au>Yang, Wen</au><au>Wang, Hongyang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2</atitle><jtitle>NPJ precision oncology</jtitle><stitle>npj Precision Onc</stitle><addtitle>NPJ Precis Oncol</addtitle><date>2018-01-08</date><risdate>2018</risdate><volume>2</volume><issue>1</issue><spage>1</spage><epage>1</epage><pages>1-1</pages><artnum>1</artnum><issn>2397-768X</issn><eissn>2397-768X</eissn><abstract>Vitamin C (L-ascorbic acid, ascorbate, VC) is a potential chemotherapeutic agent for cancer patients. However, the anti-tumor effects of pharmacologic VC on hepatocellular carcinoma (HCC) and liver cancer stem cells (CSCs) remain to be fully elucidated. Panels of human HCC cell lines as well as HCC patient-derived xenograft (PDX) models were employed to investigate the anti-tumor effects of pharmacologic VC. The use of VC and the risk of HCC recurrence were examined retrospectively in 613 HCC patients who received curative liver resection as their initial treatment. In vitro and in vivo experiments further demonstrated that clinically achievable concentrations of VC induced cell death in liver cancer cells and the response to VC was correlated with sodium-dependent vitamin C transporter 2 (SVCT-2) expressions. Mechanistically, VC uptake via SVCT-2 increased intracellular ROS, and subsequently caused DNA damage and ATP depletion, leading to cell cycle arrest and apoptosis. Most importantly, SVCT-2 was highly expressed in liver CSCs, which promoted their self-renewal and rendered them more sensitive to VC. In HCC cell lines xenograft models, as well as in PDX models, VC dramatically impaired tumor growth and eradicated liver CSCs. Finally, retrospective cohort study showed that intravenous VC use was linked to improved disease-free survival (DFS) in HCC patients (adjusted HR = 0.622, 95% CI 0.487 to 0.795,
p
< 0.001). Our data highlight that pharmacologic VC can effectively kill liver cancer cells and preferentially eradicate liver CSCs, which provide further evidence supporting VC as a novel therapeutic strategy for HCC treatment.
Liver cancer: vitamin C preferentially kills cancer stem cells and improves patient outcomes
Pharmacologic doses of vitamin C preferentially eradicate liver cancer stem cells and are associated with improved outcomes in patients. A team led by Hong-Yang Wang and Wen Yang from the Second Military Medical University in Shanghai, China, showed that clinically achievable concentrations of vitamin C effectively killed liver cancer cells and preferentially eradicated cancer stem cells in culture and in mouse transplant models. Cells with higher expression levels of a vitamin C transporter protein were more susceptible to the treatment, which explains why cancer stem cells, which highly express this transportor and use it for their own self-renewal, were especially sensitive to take in vitamin C, which led to a cascade that resulted in DNA damage, energy depletion, and ultimately cell death. A retrospective analysis of 613 patients with liver cancer showed that those who received intravenous vitamin C lived longer without disease relapse.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29872720</pmid><doi>10.1038/s41698-017-0044-8</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2397-768X |
| ispartof | NPJ precision oncology, 2018-01, Vol.2 (1), p.1-1, Article 1 |
| issn | 2397-768X 2397-768X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5871898 |
| source | Publicly Available Content Database; PubMed Central; Springer Nature - nature.com Journals - Fully Open Access |
| subjects | 631/67/1059 631/67/71 Apoptosis Cancer Research Cell cycle DNA damage Gene Therapy Human Genetics Internal Medicine Liver cancer Medicine Medicine & Public Health Oncology Patients Precision medicine Stem cells Targeted cancer therapy Vitamin C |
| title | Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A54%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20C%20preferentially%20kills%20cancer%20stem%20cells%20in%20hepatocellular%20carcinoma%20via%20SVCT-2&rft.jtitle=NPJ%20precision%20oncology&rft.au=Lv,%20Hongwei&rft.date=2018-01-08&rft.volume=2&rft.issue=1&rft.spage=1&rft.epage=1&rft.pages=1-1&rft.artnum=1&rft.issn=2397-768X&rft.eissn=2397-768X&rft_id=info:doi/10.1038/s41698-017-0044-8&rft_dat=%3Cproquest_pubme%3E2389705333%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c536t-4d41d2d460902625f8a08eef21d8a9966f2d21ddbbb325e6d14efe5903c55be73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2389705333&rft_id=info:pmid/29872720&rfr_iscdi=true |